Munich

• A phase II study evaluating the efficacy and safety of IMetelstat in Patients with HR myElodysplastic SyndromeS or AML failing HMA-based the … Not authorised
  2022-500721-32-00 4 AML and MDS patients failing or being refractory to hypomethylating ag
• A 3-month, phase 2, single-blind, randomised, no-treatment controlled study assessing efficacy and safety of Renaparin® for improvement of k … Not authorised
  2022-501389-23-00 4 end-stage renal disease or otherwise an insufficient kidney function
• Clinical trial of MK-7648A in adults and children with skin cancer Not authorised
  2022-501417-31-00 5 High-risk Resected Melanoma
• An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma Not authorised
  2022-501463-40-00 5 Locally Advanced or Metastatic Cholangiocarcinoma
• A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Pati … Not authorised
  2022-502043-35-00 5 Advanced Biliary Tract Cancers
• A clinical study of people with HIV‐1 who switch their treatment to a combination of doravirine and islatravir​​ Not authorised
  2022-502079-49-00 5 HIV-1 infection
• A clinical study of people with HIV-1 who have not taken antiretroviral therapy, one group will start treatment with a combination of doravi … Not authorised
  2022-502099-22-00 5 HIV-1 Infection
• A clinical study of people with HIV-1 who received prior treatment combination of doravirine and islatravir Not authorised
  2022-502126-40-00 5 HIV-1 infection
• Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inh … Not authorised
  2023-505311-20-00 5 Metastatic Non-Small Cell Lung Cancer
• Safety, tolerability, and efficacy of mFOLFIRINOX ±BNT321 as adjuvant therapy following curative resection in patients with pancreatic adeno … Not authorised
  2023-506014-47-00 9 Resected (R0 or R1) pancreatic ductal adenocarcinoma
• Metal Panel Patch Test Not authorised
  2023-507972-35-00 5 Allergic contact dermatitis Eczema
• Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not authorised
  2023-509861-19-00 4 Diffuse large B-cell lymphoma (DLBCL)
• Safety, Tolerability, and Imaging Quality of HarMono-T Contrast Agent During Ultrasound of the Kidney in Healthy Subjects Not authorised
  2024-514924-17-00 9 Ultrasound contrast agent, for diagnostic purposes (to assess indeterm
• A prospective, multi-centre, randomised, double-blind, placebo-controlled Phase III trial to investigate the efficacy and safety of lozenges … Not authorised
  2025-521764-35-00 5 acute pharyngitis
• A one-year study to assess if Xanomeline/Trospium (XT) can improve cognitive function in adults living with schizophrenia. Not authorised
  2025-523060-20-00 5 Schizophrenia
• A clinical study of MK-7240 for the treatment of ulcerative colitis (MK-7240-001) Unknown
  2025-523766-25-00 5 Ulcerative colitis
• Stroke in childhood due to inflammatory narrowing of blood vessels: Treatment with steroids Pending
  2022-500631-36-00 5 Focal cerebral arteriopathy and childhood stroke Focal cerebral arteri
• A 3-month, phase 2, single-blind, randomised, no-treatment controlled study assessing efficacy and safety of Renaparin® for improvement of k … Pending
  2022-501389-23-02 4 end-stage renal disease or otherwise an insufficient kidney function
• Phase 4 Paediatric Study to Evaluate Sonazoid™ Safety and Efficacy for Contrast-Enhanced Ultrasound Liver Imaging. Pending
  2023-505569-95-00 11 Focal Liver Lesion
• An adaptive open-label multicentre phase 1/2 trial, to determine the recommended phase 2 dose of CCTx-001, and to assess safety, tolerabilit … Pending
  2023-506865-71-00 7 Relapsed/Refractory Acute Myeloid Leukemia (AML)
• Investigation of breathable surfactant agent in patients with idiopathic lung fibrosis Pending
  2023-508544-22-00 4 Idiopathic pulmonary fibrosis
• A double-blinded, randomized, placebo-controlled, multi-center trial of Efgartigimod in autoimmune dementia (EfgaDem) Pending
  2023-510216-39-00 4 Autoimmune dementia
• Clinical trial to determine the efficacy and safety of AP707 in the treatment of Borderline Personality Disorder Pending
  2024-510873-11-00 4 Borderline personality disorder
• A Study of Anti-CD19 CAR T-cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis Pending
  2024-511168-10-00 4 Primary or Secondary Progressive Multiple Sclerosis

Showing 1–24 of 1,103 trials